[go: up one dir, main page]

GT200000085A - Amidas sustituidas del acido fenilciclohexanocarboxilico (inhibidores de la incorporacion de adenosina) - Google Patents

Amidas sustituidas del acido fenilciclohexanocarboxilico (inhibidores de la incorporacion de adenosina)

Info

Publication number
GT200000085A
GT200000085A GT200000085A GT200000085A GT200000085A GT 200000085 A GT200000085 A GT 200000085A GT 200000085 A GT200000085 A GT 200000085A GT 200000085 A GT200000085 A GT 200000085A GT 200000085 A GT200000085 A GT 200000085A
Authority
GT
Guatemala
Prior art keywords
therapy therapy
refers
clohexanocarboxilic
adhesine
phenyl
Prior art date
Application number
GT200000085A
Other languages
English (en)
Inventor
Erwin Bischoff
Stephan Lensky
Stephan-Nicholas Muller
Holger Paulsen
Jorg Keldenich
Thomas Krahn
Joachim Schumacher
Jan Janichen
Wolfgang Thielemann
Henning Steinhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000085A publication Critical patent/GT200000085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA I, DONDE "A,D,E Y G" SON IGUALES O DIFERENTES Y CORRESPONDEN A GRUPOS CH O ATOMOS DE NITROGENO. "L" = H, HALOGENOS, HIDROXI, CARBOXILO, CIANO, NITRO, TRIFLUOROMETILO, TRIFLUORMETOXI, ALQUILO, ALCOXI O ALCOXICARBONILO; LA INVENCION TAMBIEN SE REFIERE A LOS PROCEDIMIENTOS PARA SU OBTENCION Y A SU USO EN MEDICAMENTOS. EL COMPUESTO ES UN INHIBIDOR DE ADENOSINA LO CUAL INTENSIFICA EL EFECTO DE LA ADENOSINA LOCAL FORMADA POR LA ISQUEMIA Y DILATA POR TANTO LOS VASOS SANGUINEOS, ASI ENTONCES PUEDEN UTILIZARSE MEDIANTE ADMINISTRACION ORAL O INTRAVENOSA PARA LA PROFILAXIS Y TERAPIA DE ENFERMEDADES ISQUEMICAS, POR EJEMPLO DE ENFERMEDADES CORONARIAS, ANGINAS DE PECHO, ENFERMEDADES OCULARES, INFARTO AL MIOCARDIO, ASI MISMO SON UTILES PARA LA POTENCIACION DEL EFECTO DE ANTIMETABOLITOS NUCLEOBASICOS, NECLEOSIDOS O NUCLEOTIDOS EN EL TRATAMIENTO QUIMIOTERAPEUTICO DEL CANCER Y LA QUIMIOTERAPIA ANTIVIRICA ( POR EJEMPLO VIH). LA INVENCION TAMBIEN SE REFIERE A LOS ENANTIOMEROS Y DIASTEROISOMEROS, LAS SALES, HIDRATOS Y PROMEDICAMENTOS DEL COMPUESTO.
GT200000085A 1999-05-29 2000-05-26 Amidas sustituidas del acido fenilciclohexanocarboxilico (inhibidores de la incorporacion de adenosina) GT200000085A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924819A DE19924819A1 (de) 1999-05-29 1999-05-29 Substituierte Phenylcyclohexancarbonsäurebenzylamid (Adenosinaufnahmeinhibitoren)

Publications (1)

Publication Number Publication Date
GT200000085A true GT200000085A (es) 2001-11-17

Family

ID=7909713

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000085A GT200000085A (es) 1999-05-29 2000-05-26 Amidas sustituidas del acido fenilciclohexanocarboxilico (inhibidores de la incorporacion de adenosina)

Country Status (25)

Country Link
US (1) US6984642B1 (es)
EP (1) EP1187812B1 (es)
JP (1) JP2003500474A (es)
KR (1) KR20020000814A (es)
CN (1) CN1165526C (es)
AR (1) AR029639A1 (es)
AT (1) ATE303995T1 (es)
AU (1) AU766140B2 (es)
BR (1) BR0011049A (es)
CA (1) CA2375188A1 (es)
CO (1) CO5170503A1 (es)
DE (2) DE19924819A1 (es)
DK (1) DK1187812T3 (es)
ES (1) ES2248071T3 (es)
GT (1) GT200000085A (es)
HK (1) HK1047107B (es)
HN (1) HN2000000078A (es)
IL (1) IL146231A0 (es)
MX (1) MXPA01012240A (es)
PE (1) PE20010132A1 (es)
PL (1) PL365960A1 (es)
TR (1) TR200103398T2 (es)
UY (1) UY26179A1 (es)
WO (1) WO2000073274A2 (es)
ZA (1) ZA200108894B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10150310A1 (de) * 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
KR100762858B1 (ko) * 2005-03-07 2007-10-02 김기완 Ｐｅ시트를 이용한 저수조의 방수 공법
KR100762857B1 (ko) * 2005-03-07 2007-10-02 김기완 Ｐｅ시트를 이용한 저수조의 방수 공법
KR100745024B1 (ko) * 2005-05-09 2007-08-01 김준 거푸집 수평조절장치
JP2011528358A (ja) * 2008-07-16 2011-11-17 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のシクロヘキセニルモジュレーター
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322707T2 (de) * 1992-07-31 1999-08-19 Bristol-Myers Squibb Company Diphenyl Oxazole-, Thiazole- und Imidazole-Derivate als Inhibitoren der Wiederaufnahme des Adenosins
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
BR9610486A (pt) * 1995-09-22 1999-05-11 Sumitomo Chemical Co Derivados de pirazin-2-ona seu uso e intermediários para a sua produção
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle

Also Published As

Publication number Publication date
DE19924819A1 (de) 2000-11-30
WO2000073274A3 (de) 2001-04-19
CA2375188A1 (en) 2000-12-07
DE50011122D1 (de) 2005-10-13
AU4405700A (en) 2000-12-18
US6984642B1 (en) 2006-01-10
AU766140B2 (en) 2003-10-09
UY26179A1 (es) 2000-12-29
AR029639A1 (es) 2003-07-10
ES2248071T3 (es) 2006-03-16
CN1353693A (zh) 2002-06-12
WO2000073274A2 (de) 2000-12-07
ZA200108894B (en) 2003-01-29
PE20010132A1 (es) 2001-04-12
DK1187812T3 (da) 2005-12-12
PL365960A1 (en) 2005-01-24
IL146231A0 (en) 2002-07-25
KR20020000814A (ko) 2002-01-05
JP2003500474A (ja) 2003-01-07
HN2000000078A (es) 2001-02-02
ATE303995T1 (de) 2005-09-15
EP1187812B1 (de) 2005-09-07
MXPA01012240A (es) 2002-08-12
EP1187812A2 (de) 2002-03-20
CN1165526C (zh) 2004-09-08
CO5170503A1 (es) 2002-06-27
BR0011049A (pt) 2002-03-19
HK1047107B (zh) 2005-05-20
HK1047107A1 (en) 2003-02-07
TR200103398T2 (tr) 2002-03-21

Similar Documents

Publication Publication Date Title
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
AR007456A1 (es) Compuestos derivados de indazol sustituido y composiciones farmaceuticas que lo contienen
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
ZA200406709B (en) Pyrimidine derivatives
ES2188005T3 (es) Derivados de amidas para el tratamiento de enfermedades mediadas por citoquinas.
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
CA2497868A1 (en) Heterocyclic compounds
HN1997000046A (es) Derivados de indazol sustituidos y compuestos relacionados
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
AR027464A1 (es) Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh)
MA27654A1 (fr) DERIVES HEXAHYDROPYRAZINO [1,2-a]-4,7-DIONE SUBSTITUES, METHODE POUR LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
PA8432901A1 (es) Compuestos de piridilpirrol
TNSN06440A1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer
UY27786A1 (es) Derivados de isoquinolina.
DK1056704T3 (da) Antitumormidler
AR127497A1 (es) Derivados de piridazin-3(2h)-ona
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
GT200000085A (es) Amidas sustituidas del acido fenilciclohexanocarboxilico (inhibidores de la incorporacion de adenosina)
AR127496A1 (es) Compuestos de cd73
KR940009184A (ko) 피라졸 축합환 유도체, 이의 제조방법 및 안드로겐 억제제
ES2036137B1 (es) Procedimiento para la preparacion de la nueva 1-(3-clorofenil)-4-hidroximetil-7,8-dimetoxi-5h-2,3-benzodiacepina y de sus sales de adicion acida.
ES2062094T3 (es) Derivados del acido parabanico y composiciones farmaceuticas que los contienen.
UY27009A1 (es) Nuevos heteroaromatos